In 2001, Barbara and Edward Netter founded ACGT to accelerate progress and fund the best research at the most prestigious institutions developing cell and gene therapies for cancer. Since then, ACGT has awarded $30.2 million through 59 grants to 54 research fellows representing 36 top medical institutions in the United States and Canada.
ACGT funds the best scientists and biotechnology companies harnessing the power of cell and gene therapy to transform how cancer is treated and drive momentum toward a cure.
Our commitment is to identify, fund and monitor innovative cancer cell and gene therapy research and trials, which meet a rigorous set of scientific standards and show the potential to effectively treat cancers of all types in the foreseeable future.
Why should I support your work?
ACGT is the only U.S. non-profit dedicated exclusively to advancing cancer cell and gene therapies — effective, efficient, less toxic cancer therapies that use the body’s own genes and cells as medicine. With nearly a 20-year track record of success, ACGT is shaping an entirely new treatment paradigm for people with certain deadly cancers, including ovarian, prostate, sarcoma, glioblastoma, melanoma and pancreatic cancers.
Although ACGT-funded advances in cancer cell and gene therapy have been truly life changing for an increasing number of patients, especially those fighting blood cancers, there is an urgent need to translate this success into therapies to fight more types of cancer, such as solid tumor cancers.
Public support is critical to helping researchers overcome these challenges and related hurdles, such as side effects, cost and complexity of therapy.